Payment overview · 2025
General Payments
$193.49
9 reported records · 5 companies
Healthcare provider profile · identity verified
Elisabeth Soto, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · SAN JUAN, PR · NPI 1992881031
Verified facts
What the public records show
CMS Open Payments records show Elisabeth Soto, MD received $193.49 in general payments during 2025 across 9 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 28.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Mounjaro.
Bayer Puerto Rico Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 784 records involving 303 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Jardiance by this doctor in 2024.
Eli Lilly Export S.A. Puerto Rico Branch reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 342 records involving 186 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.15 | 28.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $52.58 | 27.2% | 3 | 2025 |
| Bayer Puerto Rico Inc. | Unresolved — no canonical attribution shown | $50.41 | 26.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.91 | 9.3% | 1 | 2025 |
| Eli Lilly Export S.A. Puerto Rico Branch | Unresolved — no canonical attribution shown | $17.44 | 9.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $193.49 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $55.15 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $52.58 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Puerto Rico Inc. | $50.41 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $17.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 190 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Puerto Rico Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 784 supporting records · 303 recipient NPIs · example record 1225435793 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
190 | 64 |
| Eli Lilly Export S.A. Puerto Rico Branch Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 342 supporting records · 186 recipient NPIs · example record 1186464879 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Synthroid | Levothyroxine Sodium | 831 | 307 |
| Metformin Hcl | Metformin Hcl | 254 | 113 |
| Jardiance | Empagliflozin | 190 | 64 |
| Ozempic | Semaglutide | 132 | 18 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 126 | 66 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 40 |
| Humalog | Insulin Lispro | 88 | 21 |
| Glipizide Er | Glipizide | 85 | 29 |
| Glimepiride | Glimepiride | 82 | 44 |
| Tradjenta | Linagliptin | 76 | 28 |
| Atorvastatin Calcium | Atorvastatin Calcium | 72 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 70 | 37 |
| Trulicity | Dulaglutide | 70 | 15 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 61 | 26 |
| Farxiga | Dapagliflozin Propanediol | 60 | 20 |
| Ezetimibe | Ezetimibe | 53 | 26 |
| Losartan Potassium | Losartan Potassium | 53 | 28 |
| Simvastatin | Simvastatin | 51 | 29 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | 30 |
| Gabapentin | Gabapentin | 47 | 28 |
| Amlodipine Besylate | Amlodipine Besylate | 40 | 28 |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | 13 |
| Januvia | Sitagliptin Phosphate | 31 | 12 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | 14 |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | 18 |
| Fluconazole | Fluconazole | 25 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 25 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 25 | 14 |
| Pen Needle | Pen Needle, Diabetic | 24 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 18 | 11 |
| Kerendia | Finerenone | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Omeprazole | Omeprazole | 13 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 13 | suppressed |
| Cabergoline | Cabergoline | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $193.49 · 9 records | Boehringer Ingelheim Pharmaceuticals, Inc. | Dexcom G6 Transmitter, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, MOUNJARO, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Puerto Rico Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error